August J. Troendle is a distinguished figure in the clinical research industry, currently serving as the Chief Executive Officer of Medpace Holdings Inc. A company he founded in 1992, Medpace has grown under Troendle's leadership to become a leading global clinical research organization (CRO) that provides Phase I-IV clinical development services to the pharmaceutical and biotechnology industries. Troendle's vision for Medpace was to create a CRO that combines scientific expertise with operational efficiency, a goal that has been realized through the company's consistent growth and strong reputation in the industry. Before founding Medpace, Troendle earned his medical degree from the University of Cincinnati College of Medicine and completed his residency in internal medicine at the University of Cincinnati Hospital. He further honed his skills with a fellowship in cardiovascular diseases at the same institution. This robust medical background has been instrumental in guiding Medpace's focus on delivering high-quality, scientifically rigorous clinical trials. Troendle's commitment to excellence is evident in Medpace's client-centric approach and its ability to attract and retain top talent in the field. As CEO, Troendle oversees all aspects of Medpace's operations, from strategic planning to the execution of clinical trials. Under his leadership, Medpace has expanded its global footprint, establishing a presence in key markets across North America, Europe, and Asia. Troendle's achievements include leading Medpace to a successful initial public offering in 2014, further solidifying the company's position as a leader in the CRO space. His dedication to innovation and quality continues to drive Medpace's success, making it a trusted partner for clients seeking to bring new therapies to market.